Novartis Ianalumab Trials Succeed in Sjögren’s Disease
August 11, 2025
NEPTUNUS-1 and NEPTUNUS-2 are the first ever global Phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s disease Novartis announced positive